作者
Yuanhui Li,Fan Wu,Weigang Ge,Yu Zhang,Y. Hu,Lingqian Zhao,Wanglong Gou,Jingjing Shi,Yeqin Ni,Lu Li,Wenxin Fu,Xiangfeng Lin,Yunxian Yu,Zhijiang Han,Chuang-Hua Chen,Rujun Xu,Shirong Zhang,Li Zhou,Gang Pan,You Peng,Linlin Mao,Tianhan Zhou,Ju‐Sheng Zheng,Haitao Zheng,Yaoting Sun,Tiannan Guo,Dingcun Luo
摘要
Background: Papillary thyroid cancer (PTC) is one of the most common endocrine malignancies with different risk levels. However, preoperative risk assessment of PTC is still a challenge in the worldwide. Here, the authors first report a Preoperative Risk Assessment Classifier for PTC (PRAC-PTC) by multidimensional features including clinical indicators, immune indices, genetic feature, and proteomics. Materials and Methods: The 558 patients collected from June 2013 to November 2020 were allocated to three groups: the discovery set [274 patients, 274 formalin-fixed paraffin-embedded (FFPE)], the retrospective test set (166 patients, 166 FFPE), and the prospective test set (118 patients, 118 fine-needle aspiration). Proteomic profiling was conducted by FFPE and fine-needle aspiration tissues from the patients. Preoperative clinical information and blood immunological indices were collected. The BRAF V600E mutation were detected by the amplification refractory mutation system. Results: The authors developed a machine learning model of 17 variables based on the multidimensional features of 274 PTC patients from a retrospective cohort. The PRAC-PTC achieved areas under the curve (AUC) of 0.925 in the discovery set and was validated externally by blinded analyses in a retrospective cohort of 166 PTC patients (0.787 AUC) and a prospective cohort of 118 PTC patients (0.799 AUC) from two independent clinical centres. Meanwhile, the preoperative predictive risk effectiveness of clinicians was improved with the assistance of PRAC-PTC, and the accuracies reached at 84.4% (95% CI: 82.9–84.4) and 83.5% (95% CI: 82.2–84.2) in the retrospective and prospective test sets, respectively. Conclusion: This study demonstrated that the PRAC-PTC that integrating clinical data, gene mutation information, immune indices, high-throughput proteomics and machine learning technology in multicentre retrospective and prospective clinical cohorts can effectively stratify the preoperative risk of PTC and may decrease unnecessary surgery or overtreatment.